These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 2703405

  • 1. Structure-activity relationships for benzotriazine di-N-oxides.
    Zeman EM, Baker MA, Lemmon MJ, Pearson CI, Adams JA, Brown JM, Lee WW, Tracy M.
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):977-81. PubMed ID: 2703405
    [Abstract] [Full Text] [Related]

  • 2. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
    Monge A, Palop JA, López de Ceráin A, Senador V, Martínez-Crespo FJ, Sainz Y, Narro S, García E, de Miguel C, González M.
    J Med Chem; 1995 May 12; 38(10):1786-92. PubMed ID: 7752202
    [Abstract] [Full Text] [Related]

  • 3. Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions.
    Silva JM, O'Brien PJ.
    Br J Cancer; 1993 Sep 12; 68(3):484-91. PubMed ID: 8394729
    [Abstract] [Full Text] [Related]

  • 4. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR.
    Cancer Res; 2004 Jan 15; 64(2):736-42. PubMed ID: 14744792
    [Abstract] [Full Text] [Related]

  • 5. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
    Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW.
    Int J Radiat Oncol Biol Phys; 1986 Jul 15; 12(7):1239-42. PubMed ID: 3744945
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
    Zeman EM, Hirst VK, Lemmon MJ, Brown JM.
    Radiother Oncol; 1988 Jul 15; 12(3):209-18. PubMed ID: 3175048
    [Abstract] [Full Text] [Related]

  • 7. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM.
    Br J Cancer; 1993 Jun 15; 67(6):1163-70. PubMed ID: 8512801
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
    Walton MI, Workman P.
    J Pharmacol Exp Ther; 1993 May 15; 265(2):938-47. PubMed ID: 8496834
    [Abstract] [Full Text] [Related]

  • 9. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
    Hunter FW, Wang J, Patel R, Hsu HL, Hickey AJ, Hay MP, Wilson WR.
    Biochem Pharmacol; 2012 Mar 01; 83(5):574-85. PubMed ID: 22182429
    [Abstract] [Full Text] [Related]

  • 10. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
    Elwell JH, Siim BG, Evans JW, Brown JM.
    Biochem Pharmacol; 1997 Jul 15; 54(2):249-57. PubMed ID: 9271329
    [Abstract] [Full Text] [Related]

  • 11. Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo.
    Minchinton AI, Lemmon MJ, Tracy M, Pollart DJ, Martinez AP, Tosto LM, Brown JM.
    Int J Radiat Oncol Biol Phys; 1992 Jul 15; 22(4):701-5. PubMed ID: 1544841
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075).
    Riley RJ, Hemingway SA, Graham MA, Workman P.
    Biochem Pharmacol; 1993 Mar 09; 45(5):1065-77. PubMed ID: 8461036
    [Abstract] [Full Text] [Related]

  • 14. SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures.
    Biedermann KA, Wang J, Graham RP, Brown JM.
    Br J Cancer; 1991 Mar 09; 63(3):358-62. PubMed ID: 2003976
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of the benzotriazine dioxide SR 4233 against human tumour colony-forming units.
    Hanauske AR, Ross M, Degen D, Hilsenbeck SG, Von Hoff DD.
    Eur J Cancer; 1993 Mar 09; 29A(3):423-5. PubMed ID: 8398345
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.
    Graham MA, Senan S, Robin H, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R, Workman P.
    Cancer Chemother Pharmacol; 1997 Mar 09; 40(1):1-10. PubMed ID: 9137522
    [Abstract] [Full Text] [Related]

  • 17. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin.
    Walton MI, Workman P.
    Biochem Pharmacol; 1990 Jun 01; 39(11):1735-42. PubMed ID: 2344370
    [Abstract] [Full Text] [Related]

  • 18. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
    Hay MP, Gamage SA, Kovacs MS, Pruijn FB, Anderson RF, Patterson AV, Wilson WR, Brown JM, Denny WA.
    J Med Chem; 2003 Jan 02; 46(1):169-82. PubMed ID: 12502371
    [Abstract] [Full Text] [Related]

  • 19. Putative electron-affinic radiosensitizers and markers of hypoxic tissue: Synthesis and preliminary in vitro biological characterization of C3-amino-substituted benzotriazine dioxides (BTDOs).
    Elsaidi HR, Yang XH, Ahmadi F, Weinfeld M, Wiebe LI, Kumar P.
    Eur J Med Chem; 2019 Mar 01; 165():216-224. PubMed ID: 30684798
    [Abstract] [Full Text] [Related]

  • 20. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
    Brown JM, Lemmon MJ.
    Radiother Oncol; 1991 Mar 01; 20 Suppl 1():151-6. PubMed ID: 2020764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.